BNXT:CA BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)

CAD 0.38 0.00 0
Icon

BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) (BNXT:CA) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - Specialty & Generic | CNSX
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

CAD 0.38

0.00 (0.00)%

CAD 0.04B

0.03M

N/A

N/A

Icon

BNXT:CA

BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) (CAD)
COMMON STOCK | CNSX
CAD 0.38
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

CAD 0.04B

N/A

CAD 0.38

BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) (BNXT:CA) Stock Forecast

N/A

Based on the BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) stock forecast from 0 analysts, the average analyst target price for BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) is not available over the next 12 months. BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) is Slightly Bearish, which is based on 1 positive signals and 2 negative signals. At the last closing, BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)’s stock price was CAD 0.38. BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)’s stock price has changed by -15.56% over the past week, -33.33% over the past month and 0% over the last year.

No recent analyst target price found for BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)
No recent average analyst rating found for BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)

Company Overview BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)

BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, the United States, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psyched...Read More

N/A

N/A

0

N/A

CAD

Canada

Adjusted Closing Price for BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) (BNXT:CA)

Loading...

Unadjusted Closing Price for BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) (BNXT:CA)

Loading...

Share Trading Volume for BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) Shares

Loading...

Compare Performance of BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BNXT:CA

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
GTII:CA
Green Thumb Industries Inc 0.00 (0.00%) CAD4.16B 83.62 14.57

ETFs Containing BNXT:CA

Symbol Name BNXT:CA's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) (BNXT:CA) Stock

Stock Target Advisor's fundamental analysis for BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)'s stock is Slightly Bearish.

Unfortunately we do not have enough data on BNXT:CA's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on BNXT:CA's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on BNXT:CA's stock to indicate if its overvalued.

The last closing price of BNXT:CA's stock was CAD 0.38.

The most recent market capitalization for BNXT:CA is CAD 0.04B.

Unfortunately we do not have enough analyst data on BNXT:CA's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)'s stock.

As per our most recent records BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) has 0 Employees.

Sorry we do not have any infomation available on BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)'s address.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...